Want to see AU:GSS full AI Analyst Report?

Genetic Signatures Ltd. (GSS) Price & Analysis

8 Followers

GSS Stock Chart & Stats

AU$0.24

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.24

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.43

Previous CloseN/A

Volume34.30K

Average Volume (3M)430.89K

Market Cap

AU$16.58M

Enterprise Value-AU$6.57

Total Cash (Recent Filing)AU$22.09M

Total Debt (Recent Filing)AU$310.00K

Price to Earnings (P/E)―

Beta0.60

Next Earnings

Feb 16, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding227,138,820

10 Day Avg. Volume414,825

30 Day Avg. Volume430,892

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.43

Price to Sales (P/S)1.05

P/FCF Ratio-1.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)AU$21.80M

Bulls Say, Bears Say

Bulls Say

Proprietary Diagnostic PlatformOwnership of a proprietary molecular-diagnostics platform can support differentiated assay development, workflow integration and expansion into gastrointestinal, respiratory and other pathogen-testing markets.

Recurring Consumables ModelConsumable assay sales can create repeat purchasing as laboratories run routine infectious-disease tests, providing a recurring revenue foundation tied to customer testing volumes and workflow adoption.

Very Low LeverageMinimal debt reduces refinancing and solvency risk, preserves financial flexibility and limits interest burdens while the company works to improve operations and restore sustainable cash generation.

Bears Say

Declining RevenuePersistent revenue contraction suggests weaker demand, customer adoption or commercial execution. Without a durable return to growth, fixed costs become harder to absorb and the platform’s market opportunity may not translate into scale.

Severe UnprofitabilityDeeply negative margins indicate the current business is not covering product and operating costs. Sustained losses can constrain investment, weaken negotiating power and require restructuring or additional funding to reach viability.

Ongoing Cash BurnMulti-year negative operating and free cash flow shows that operations are not self-funding. Continued cash burn can erode liquidity and equity, limiting the company’s ability to commercialize products without external capital.

Genetic Signatures Ltd. News

Genetic Signatures Faces Shareholder-Requested Vote on Director Removal

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an announcement. Genetic Signatures Ltd, a molecular diagnostics firm focused...

12h ago

GSS

Genetic Signatures Sets 2026 AGM Date and Director Nomination Deadline

Genetic Signatures Ltd. ( ($AU:GSS) ) has issued an announcement. Genetic Signatures Ltd has scheduled its 2026 Annual...

4d ago

GSS

Genetic Signatures Announces Departure of Director Caroline Waldron

Genetic Signatures Ltd. ( ($AU:GSS) ) has issued an update. Genetic Signatures Ltd has announced that non-executive director...

16d ago

GSS

Mercer Investments Withdraws as Substantial Holder in Genetic Signatures

Genetic Signatures Ltd. ( ($AU:GSS) ) just unveiled an announcement. Mercer Investments (Australia) Limited, acting in various trustee...

21d ago

GSS

Genetic Signatures in Early Merger Talks With Microba to Build Infectious Disease Diagnostics Group

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an update. Genetic Signatures Ltd has entered preliminary talks with...

23d ago

GSS

Genetic Signatures Files ASX Corporate Governance Statement for 2026

Genetic Signatures Ltd. ( ($AU:GSS) ) just unveiled an update. Genetic Signatures Ltd has lodged its annual corporate...

23d ago

GSS

Genetic Signatures Tightens Losses and Restructures as Long-Term Deals Underpin Growth Plans

Genetic Signatures Ltd. ( ($AU:GSS) ) just unveiled an update. Genetic Signatures reported FY2026 revenue of $14.8 million,...

24d ago

GSS

Genetic Signatures Sets Date for FY2026 Results and Investor Briefing

An update from Genetic Signatures Ltd. ( ($AU:GSS) ) is now available. Genetic Signatures Ltd., a global molecular...

24d ago

GSS

Genetic Signatures Cuts Costs, Secures Danish Deal and Resets Global Growth Strategy

Genetic Signatures Ltd. ( ($AU:GSS) ) has provided an update. Genetic Signatures has completed an organisational restructuring that...

2M ago

GSS

Genetic Signatures plays down BCAL stake, stresses business as usual

Genetic Signatures Ltd. ( ($AU:GSS) ) has shared an update. Genetic Signatures has responded to BCAL Diagnostics’ announcement...

3M ago

GSS

GSS FAQ

What was Genetic Signatures Ltd.’s price range in the past 12 months?

Genetic Signatures Ltd. lowest share price was AU$0.05 and its highest was AU$0.43 in the past 12 months.

What is Genetic Signatures Ltd.’s market cap?

Genetic Signatures Ltd.’s market cap is AU$16.58M.

When is Genetic Signatures Ltd.’s upcoming earnings report date?

Genetic Signatures Ltd.’s upcoming earnings report date is Feb 16, 2027 which is in 152 days.

How were Genetic Signatures Ltd.’s earnings last quarter?

Genetic Signatures Ltd. released its earnings results on Aug 24, 2026. The company reported -AU$0.034 earnings per share for the quarter.

Is Genetic Signatures Ltd. overvalued?

According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genetic Signatures Ltd. pay dividends?

Genetic Signatures Ltd. does not currently pay dividends.

What is Genetic Signatures Ltd.’s EPS estimate?

Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genetic Signatures Ltd. have?

Genetic Signatures Ltd. has 227,138,820 shares outstanding.

What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?

Genetic Signatures Ltd. reported an EPS of -AU$0.034 in its last earnings report. Following the earnings report the stock price went up 9.589%.

Which hedge fund is a major shareholder of Genetic Signatures Ltd.?

Currently, no hedge funds are holding shares in AU:GSS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Genetic Signatures Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-29.61%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Genetic Signatures Ltd.

Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.